Currently three HDAC inhibitors have been approved by the FDA where the use of vorinostat and romidepsin against refractory cutaneous and peripheral T cell lymphoma has been the most successful clinical applications of HDACis. Better understanding of the functioning of the HDACs has led to the development of new therapies that exert their effects through inhibiting it. These drugs have the potential to offer great advantages to other treatments currently in use.